 | • レポートコード：MRC2303J0169 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、255ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、世界のハイコンテントスクリーニング（HCS）市場規模が2021年に694.20百万ドル、2022年には763.52百万ドルに到達し、今後CAGR 10.16％で成長して2027年までに1,240.79百万ドルまで拡大すると予測しています。当調査資料では、ハイコンテントスクリーニング（HCS）の世界市場について調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（付属品、消耗品、器具、サービス、ソフトウェア）分析、用途別（探索的スクリーニング、腫瘍、ターゲット検証、神経生物学、毒物学）分析、エンドユーザー別（バイオテクノロジー、教育機関、政府機関、独立CRO、製薬＆医療）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめております。なお、当書に掲載されている企業情報には、Advanced Solutions Life Sciences, LLC、Aurora Biomed Inc.、Axxam S.p.A、Becton, Dickinson and Company、Bio-Rad Laboratories, Inc.、BioTek Instruments, Inc. by Agilent Technologies Inc.、Cell Signalling Technologies, Inc、Danaher Corporationなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のハイコンテントスクリーニング（HCS）市場規模：製品別 - 付属品の市場規模 - 消耗品の市場規模 - 器具の市場規模 - サービスの市場規模 - ソフトウェアの市場規模 ・世界のハイコンテントスクリーニング（HCS）市場規模：用途別 - 探索的スクリーニングにおける市場規模 - 腫瘍における市場規模 - ターゲット検証における市場規模 - 神経生物学における市場規模 - 毒物学における市場規模 ・世界のハイコンテントスクリーニング（HCS）市場規模：エンドユーザー別 - バイオテクノロジーにおける市場規模 - 教育機関における市場規模 - 政府機関における市場規模 - 独立CROにおける市場規模 - 製薬＆医療における市場規模 ・世界のハイコンテントスクリーニング（HCS）市場規模：地域別 - 南北アメリカのハイコンテントスクリーニング（HCS）市場規模 アメリカのハイコンテントスクリーニング（HCS）市場規模 カナダのハイコンテントスクリーニング（HCS）市場規模 ブラジルのハイコンテントスクリーニング（HCS）市場規模 ... - アジア太平洋のハイコンテントスクリーニング（HCS）市場規模 日本のハイコンテントスクリーニング（HCS）市場規模 中国のハイコンテントスクリーニング（HCS）市場規模 インドのハイコンテントスクリーニング（HCS）市場規模 韓国のハイコンテントスクリーニング（HCS）市場規模 台湾のハイコンテントスクリーニング（HCS）市場規模 ... - ヨーロッパ/中東/アフリカのハイコンテントスクリーニング（HCS）市場規模 イギリスのハイコンテントスクリーニング（HCS）市場規模 ドイツのハイコンテントスクリーニング（HCS）市場規模 フランスのハイコンテントスクリーニング（HCS）市場規模 ロシアのハイコンテントスクリーニング（HCS）市場規模 ... - その他地域のハイコンテントスクリーニング（HCS）市場規模 ・競争状況 ・企業情報 |
The Global High Content Screening Market size was estimated at USD 694.20 million in 2021 and expected to reach USD 763.52 million in 2022, and is projected to grow at a CAGR 10.16% to reach USD 1,240.79 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the High Content Screening to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Accessories, Consumables, Instruments, Services, and Software. The Consumables is further studied across Microplates and Reagents & Assay Kits. The Instruments is further studied across Cell Imaging & Analysis Systems and Flow Cytometers.
Based on Application, the market was studied across Explorative Screening, Neurobiology, Oncology, Target Validation, and Toxicology.
Based on End User, the market was studied across Biotechnology, Educational Institutions, Government Organizations, Independent CRO, and Pharmaceutical & Healthcare.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for High Content Screening market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the High Content Screening Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global High Content Screening Market, including Advanced Solutions Life Sciences, LLC, Aurora Biomed Inc., Axxam S.p.A, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioTek Instruments, Inc. by Agilent Technologies Inc., Cell Signalling Technologies, Inc, Danaher Corporation, Genedata AG, Merck KGaA, Ncardia BV, Olympus Corporation, Perkinelmer, Inc., PhenoVista Biosciences, Sartorius AG, SPT Labtech Ltd, Sysmex Corporation, Tecan Group Ltd., Tecan Trading AG, Thermo Fisher Scientific Inc., Thorlabs, Inc., and Yokogawa Electric Corporation.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global High Content Screening Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global High Content Screening Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global High Content Screening Market?
4. What is the competitive strategic window for opportunities in the Global High Content Screening Market?
5. What are the technology trends and regulatory frameworks in the Global High Content Screening Market?
6. What is the market share of the leading vendors in the Global High Content Screening Market?
7. What modes and strategic moves are considered suitable for entering the Global High Content Screening Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing application of high-content screening in life science research
5.1.1.2. Advancements in the imaging solutions
5.1.1.3. Favourable government regulations and investment in the developed countries
5.1.2. Restraints
5.1.2.1. Higher costs, limited availability, and difficulty of chemical synthesis for screening compounds
5.1.3. Opportunities
5.1.3.1. Technological advancement in the high throughput screening for drug discovery
5.1.3.2. Amalgamation of high throughput 3D cell-based models with advances in material sciences
5.1.4. Challenges
5.1.4.1. Lack of healthcare infrastructure and investments for HCS in emerging economies
5.2. Cumulative Impact of COVID-19
6. High Content Screening Market, by Product
6.1. Introduction
6.2. Accessories
6.3. Consumables
6.4.1. Microplates
6.4.2. Reagents & Assay Kits
6.4. Instruments
6.5.1. Cell Imaging & Analysis Systems
6.5.2. Flow Cytometers
6.5. Services
6.6. Software
7. High Content Screening Market, by Application
7.1. Introduction
7.2. Explorative Screening
7.3. Neurobiology
7.4. Oncology
7.5. Target Validation
7.6. Toxicology
8. High Content Screening Market, by End User
8.1. Introduction
8.2. Biotechnology
8.3. Educational Institutions
8.4. Government Organizations
8.5. Independent CRO
8.6. Pharmaceutical & Healthcare
9. Americas High Content Screening Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific High Content Screening Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa High Content Screening Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Advanced Solutions Life Sciences, LLC
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Aurora Biomed Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Axxam S.p.A
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Becton, Dickinson and Company
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bio-Rad Laboratories, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. BioTek Instruments, Inc. by Agilent Technologies Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Cell Signalling Technologies, Inc
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Danaher Corporation
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Genedata AG
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Merck KGaA
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Ncardia BV
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Olympus Corporation
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Perkinelmer, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. PhenoVista Biosciences
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Sartorius AG
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. SPT Labtech Ltd
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Sysmex Corporation
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Tecan Group Ltd.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Tecan Trading AG
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Thermo Fisher Scientific Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Thorlabs, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Yokogawa Electric Corporation
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing